These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

476 related articles for article (PubMed ID: 34722237)

  • 1. Homologous Recombination Deficiency Assays in Epithelial Ovarian Cancer: Current Status and Future Direction.
    Chiang YC; Lin PH; Cheng WF
    Front Oncol; 2021; 11():675972. PubMed ID: 34722237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer.
    Miller RE; Leary A; Scott CL; Serra V; Lord CJ; Bowtell D; Chang DK; Garsed DW; Jonkers J; Ledermann JA; Nik-Zainal S; Ray-Coquard I; Shah SP; Matias-Guiu X; Swisher EM; Yates LR
    Ann Oncol; 2020 Dec; 31(12):1606-1622. PubMed ID: 33004253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on Poly ADP-Ribose Polymerase Inhibitors in Ovarian Cancer With Non-BRCA Mutations.
    Xu Q; Li Z
    Front Pharmacol; 2021; 12():743073. PubMed ID: 34912215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
    Liu FW; Tewari KS
    Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Homologous recombination repair deficiency (HRD) testing in newly diagnosed advanced-stage epithelial ovarian cancer: A Belgian expert opinion.
    Vergote I; Denys H; Altintas S; Kerger J; Baurain JF; Bours V; Henry S; Van de Vijver K; Lambrechts D; Gennigens C
    Facts Views Vis Obgyn; 2022 Jun; 14(2):111-120. PubMed ID: 35781107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a 3D functional assay and identification of biomarkers, predictive for response of high-grade serous ovarian cancer (HGSOC) patients to poly-ADP ribose polymerase inhibitors (PARPis): targeted therapy.
    Sheta R; Bachvarova M; Plante M; Renaud MC; Sebastianelli A; Gregoire J; Navarro JM; Perez RB; Masson JY; Bachvarov D
    J Transl Med; 2020 Nov; 18(1):439. PubMed ID: 33213473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of homologous recombination deficiency testing in ovarian cancer and its clinical implications: do we need it?
    Ngoi NYL; Tan DSP
    ESMO Open; 2021 Jun; 6(3):100144. PubMed ID: 34015643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low testing rates and high
    Syed N; Chintakuntlawar AV; Vilasini D; Al Salami AM; Al Hasan R; Afrooz I; Uttam Chandani K; Chandani AU; Chehal A
    World J Clin Oncol; 2024 Jul; 15(7):848-858. PubMed ID: 39071455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomarker Assessment of Homologous Recombination Deficiency in Epithelial Ovarian Cancer: Association With Progression-Free Survival After Surgery.
    Yi H; Li L; Huang J; Ma Z; Li H; Chen J; Zheng X; Chen J; He H; Song J
    Front Mol Biosci; 2022; 9():906922. PubMed ID: 35769916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Poly (adenosine diphosphate-ribose) polymerase inhibitors in the treatment of triple-negative breast cancer with homologous repair deficiency.
    Yuan P; Ma N; Xu B
    Med Res Rev; 2024 Nov; 44(6):2774-2792. PubMed ID: 38922930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cracking the homologous recombination deficiency code: how to identify responders to PARP inhibitors.
    Paulet L; Trecourt A; Leary A; Peron J; Descotes F; Devouassoux-Shisheboran M; Leroy K; You B; Lopez J
    Eur J Cancer; 2022 May; 166():87-99. PubMed ID: 35279473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Limitations of homologous recombination status testing and poly (ADP-ribose) polymerase inhibitor treatment in the current management of ovarian cancer.
    Zhao Q; Bai L; Tan Y; Qie M
    Front Oncol; 2024; 14():1435029. PubMed ID: 39104720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modification of Homologous Recombination Deficiency Score Threshold and Association with Long-Term Survival in Epithelial Ovarian Cancer.
    How JA; Jazaeri AA; Fellman B; Daniels MS; Penn S; Solimeno C; Yuan Y; Schmeler K; Lanchbury JS; Timms K; Lu KH; Yates MS
    Cancers (Basel); 2021 Feb; 13(5):. PubMed ID: 33668244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging drugs for the treatment of ovarian cancer: a focused review of PARP inhibitors.
    Lee EK; Matulonis UA
    Expert Opin Emerg Drugs; 2020 Jun; 25(2):165-188. PubMed ID: 32569489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How BRCA and homologous recombination deficiency change therapeutic strategies in ovarian cancer: a review of literature.
    Arcieri M; Tius V; Andreetta C; Restaino S; Biasioli A; Poletto E; Damante G; Ercoli A; Driul L; Fagotti A; Lorusso D; Scambia G; Vizzielli G
    Front Oncol; 2024; 14():1335196. PubMed ID: 38525421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RAD51-Mediated DNA Homologous Recombination Is Independent of
    Sinha A; Saleh A; Endersby R; Yuan SH; Chokshi CR; Brown KR; Kuzio B; Kauppinen T; Singh SK; Baker SJ; McKinnon PJ; Katyal S
    Cancers (Basel); 2020 Oct; 12(11):. PubMed ID: 33138032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maintenance therapy for newly diagnosed epithelial ovarian cancer- a review.
    J Ovarian Res; ; . PubMed ID: 35902911
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 24.